NewAmsterdam Pharma’s lead cardio program obicetrapib passed another Phase 3 trial, demonstrating its ability to lower “bad cholesterol” in combination with a drug called ezetimibe.
The TANDEM study enrolled 407 patients with atherosclerotic cardiovascular disease ...
↧